menu
    • menu

    Company profile for Aktis Oncology

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital with its seasoned team of entrepreneurs and drug developers, Aktis has developed proprietary platforms to generate tumor targeting agents with ideal properties for radiotherapy. Designed for high tumor penetration a...
    Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital with its seasoned team of entrepreneurs and drug developers, Aktis has developed proprietary platforms to generate tumor targeting agents with ideal properties for radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology’s molecules can quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing side effects of treatment.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aktis OncologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    17 Drydock Avenue, Suite #17-401, Boston, MA 02210
    Telephone
    Telephone
    202.930.4762
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aktisoncology.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aktis Oncology To Present At Upcoming March Investor Conferences
    Aktis Oncology To Present At Upcoming March Investor Conferences

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3244020/0/en/Aktis-Oncology-to-Present-at-Upcoming-March-Investor-Conferences.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Aktis Oncology Closes Upsized IPO; Underwriters Exercise Option
    Aktis Oncology Closes Upsized IPO; Underwriters Exercise Option

    13 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/13/3217602/0/en/Aktis-Oncology-Announces-Closing-of-Upsized-Initial-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html

    GLOBENEWSWIRE
    13 Jan 2026
    Share Share
    Vida Ventures Applauds Aktis Oncology's Public Market Debut
    Vida Ventures Applauds Aktis Oncology's Public Market Debut

    09 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260109857776/en/Vida-Ventures-Congratulates-Aktis-Oncology-on-Its-Entry-into-the-Public-Markets

    BUSINESSWIRE
    09 Jan 2026
    Share Share
    Aktis Aims For $209M Windfall From 1St Biotech IPO Of 2026
    Aktis Aims For $209M Windfall From 1St Biotech IPO Of 2026

    05 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/aktis-oncology-aims-209m-windfall-1st-biotech-ipo-2026

    FIERCE BIOTECH
    05 Jan 2026
    Share Share
    Big Pharma-Backed Aktis Plans IPO To Fund Radiopharma Trials
    Big Pharma-Backed Aktis Plans IPO To Fund Radiopharma Trials

    22 Dec 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/big-pharma-backed-aktis-plans-ipo-fund-radiopharma-trials

    FIERCE BIOTECH
    22 Dec 2025
    Share Share
    Aktis Oncology files for US IPO as biotech listings rebound
    Aktis Oncology files for US IPO as biotech listings rebound

    19 Dec 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/aktis-oncology-files-us-ipo-biotech-listings-rebound-2025-12-19/

    REUTERS
    19 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search